<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Novo Nordisk A/S (NONOF)</title>
    <description>Latest news, press releases, and SEC filings for Novo Nordisk A/S (NONOF)</description>
    <link>https://caymanjournal.com/stock/NONOF</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Mon, 27 Apr 2026 18:46:56 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/NONOF/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>6-K — NOVO NORDISK A S</title>
      <description># 📄 What This Document Is ✨
This document is a Form 6-K, which is a report filed with the U.S. Securities and Exchange Commission (SEC) by a foreign private issuer (Novo Nordisk). 📄 Think of this as a major public announcement that provides critical updates to investors about a key drug candidate.</description>
      <link>https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002549</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002549</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>6-K — NOVO NORDISK A S</title>
      <description># 📰 What This Document Is 📜
This filing is a Form 6-K, which is a report used by foreign private issuers—companies that list shares in the U.S. but are headquartered elsewhere—to provide updates on material events. Since Novo Nordisk is a Danish company, the 6-K acts like a formal announcement to </description>
      <link>https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002554</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002554</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>6-K — NOVO NORDISK A S</title>
      <description># 📄 What This Document Is
This is a **Form 6-K** filing with the U.S. Securities and Exchange Commission (SEC). It&apos;s a routine report from a foreign company (Novo Nordisk, based in Denmark) to update American investors on a specific, important action: the progress of its share buyback program.

👉 </description>
      <link>https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002279</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002279</guid>
      <pubDate>Tue, 07 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item><item>
      <title>6-K — NOVO NORDISK A S</title>
      <description># 🧾 What This Document Is
This is a **Form 6-K**, a standard report that foreign companies like Novo Nordisk file with the U.S. SEC to keep American investors informed. This specific report is a routine update on their ongoing share buyback program.

👉 In simple terms: It’s a public receipt showin</description>
      <link>https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002013</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/NONOF/sec-filing/0001171843-26-002013</guid>
      <pubDate>Mon, 30 Mar 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>